Literature DB >> 2819246

Monoclonal and oligoclonal gammopathy after bone marrow transplantation.

A J Mitus1, R Stein, J M Rappeport, J H Antin, H J Weinstein, C A Alper, B R Smith.   

Abstract

Serial serum protein electrophoreses were performed on 60 patients undergoing allogeneic and syngeneic bone marrow transplantation (BMT). More than 50% of patients (31 of 60) developed transient oligoclonal and monoclonal gammopathies that appeared an average of 84 days posttransplantation (range 27 to 336 days) and persisted an average of 175 days (range 14 to 652 days). Immunofixation analysis revealed 82% of the M components to be of the immunoglobulin G (IgG) type and 18% to be IgM; 56% were kappa and 44% were lambda. A strong correlation between development of graft versus host disease (GVHD) and appearance of M components was observed (73% incidence in GVHD patients v 27% in non-GVHD patients, P = .0003). Two of the three syngeneic graft recipients also developed monoclonal gammopathies. Evidence of oligoclonal circulating B-cell populations was found in 68% of patients posttransplantation by flow cytometric B-cell clonal excess assay. No correlation of recovery of particular B- or T-lymphocyte subsets and development of M components was seen. The development of transient oligoclonal and monoclonal gammopathies after transplantation may be a ubiquitous finding reflecting recapitulation of early B-cell ontogeny.

Entities:  

Mesh:

Year:  1989        PMID: 2819246

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.

Authors:  Rishi K Wadhera; Robert A Kyle; Dirk R Larson; Angela Dispenzieri; Shaji Kumar; Hillard M Lazarus; S Vincent Rajkumar
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

Review 2.  Immune reconstitution following bone marrow transplantation.

Authors:  U N Verma; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

3.  Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.

Authors:  Patrizia Chiusolo; Elisabetta Metafuni; Paola Cattani; Nicola Piccirillo; Rosaria Santangelo; Stefania Manzara; Silvia Bellesi; Teresa De Michele; Giuseppe Leone; Simona Sica
Journal:  J Clin Immunol       Date:  2010-08-25       Impact factor: 8.317

4.  Laboratory persistence and clinical progression of small monoclonal abnormalities.

Authors:  David L Murray; Justin L Seningen; Angela Dispenzieri; Melissa R Snyder; Robert A Kyle; S Vincent Rajkumar; Jerry A Katzmann
Journal:  Am J Clin Pathol       Date:  2012-10       Impact factor: 2.493

5.  Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.

Authors:  Tomer Mark; David Jayabalan; Morton Coleman; Roger N Pearse; Y Lynn Wang; Richard Lent; Paul J Christos; Joong W Lee; Yash P Agrawal; Susan Matthew; Scott Ely; Madhu Mazumdar; Ethel Cesarman; John P Leonard; Richard R Furman; Selina Chen-Kiang; Ruben Niesvizky
Journal:  Br J Haematol       Date:  2008-10-16       Impact factor: 6.998

6.  Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.

Authors:  Eric A Engels; Barbara Savoldo; Ruth M Pfeiffer; Rene Costello; Adriana Zingone; Helen E Heslop; Ola Landgren
Journal:  Transplantation       Date:  2013-02-15       Impact factor: 4.939

Review 7.  B cells and transplantation: an educational resource.

Authors:  Trudy N Small; William H Robinson; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

8.  Characterization of clonality of Epstein-Barr virus-induced human B lymphoproliferative disease in mice with severe combined immunodeficiency.

Authors:  H Nakamine; A S Masih; M Okano; Y Taguchi; S J Pirruccello; J R Davis; M L Mahloch; K W Beisel; K Kleveland; W G Sanger
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

9.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

10.  Monoclonal gammopathy (IgA: lambda) after autologous T-cell-depleted bone marrow transplantation in a patient with non-Hodgkin's lymphoma.

Authors:  S Hashino; M Imamura; S Kobayashi; H Kobayashi; M Kasai; T Miyazaki
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.